French pharma major, Sanofi is aiming to secure its fair share of the Indian pharmaceutical market. Their plans involve the introduction of new drugs, boosting localisation efforts and expanding the market reach of existing brands through partnerships with local drug firms, according to a top company official.
Sanofi is gearing up to strengthen its presence in the diabetes segment and bolster its consumer healthcare division, which has been spun off into a separate entity. Simultaneously, they are exploring avenues for local production of their top-notch products within India.
Rodolfo Hrosz, Managing Director of Sanofi India, emphasised the company’s commitment to accelerated growth in the Indian market. He highlighted the significant potential that India holds, both presently and in the foreseeable future, underscoring the company’s ambition to secure a more substantial foothold.
Focus on diabetes solutions and global expansion
Diabetes emerges as a focal point for Sanofi in India, recognising it as a significant health challenge. Hrosz expressed the company’s dedication to addressing this issue by providing innovative therapies tailored for the Indian populace. He unveiled plans to introduce Soliqua, a premix insulin product, catering to the evolving needs of diabetes management. Additionally, Sanofi is poised to bring several globally acclaimed products to India, with a robust pipeline of 12 forthcoming launches in the country.
Among these, Dupixent stands out as the pioneering biologic medicine for treating moderate-to-severe atopic dermatitis in adults. Hrosz outlined a series of other promising products such as Xenpozyme, Nexviazyme, Beyfortus, and Rezurock, slated for release in the coming years.
Sanofi strengthens manufacturing in India
Sanofi’s manufacturing operations in India are formidable, collaborating with 15 contract manufacturing organisations and maintaining its manufacturing footprint in Goa. Leveraging this robust production infrastructure remains a key priority for the company.
Moreover, Sanofi has forged strategic alliances with prominent Indian pharmaceutical firms like Cipla, Dr. Reddy’s Laboratories, and Emcure to broaden the market penetration of its products. Hrosz underscored the importance of these collaborations in extending the reach of Sanofi’s offerings across India, outlining a clear strategy for maximising the impact of existing products.
(With inputs from PTI)